Seattle, WA -- (SBWIRE) -- 11/06/2019 -- Tissue engineering is an advanced technology that is used to develop functional three-dimensional tissues combining cells, scaffolds, and bioactive molecules. Tissue engineering is basically used to restore or construct injured body parts or tissue. Moreover, it is also used in the regeneration of damaged tissues by combining cells from the body with highly porous scaffold biomaterials and scaffold biomaterials act as patterns for tissue regeneration and promote the growth of new tissue. Therefore, tissue regeneration is an ideal technique for clinical management of organ therapeutics such as organ transplantation. The cells used in tissue culturing engineering can be autologous (isolate from patients), allogeneic (from a donor), and xenogenic (from different species)
Tissue engineering is gaining traction in the market on the account of rising applications across wound care, burn treatment, orthopedics, neurology, urological products, and others. It's also play an important role in the management of pediatric patients when any organ or tissue is absent at the time of birth such as congenital anomalies. Moreover, increasing burn and trauma-related injuries are expected to drive the global tissue engineering market growth. According to the American Burn Association 2014 data, nearly 450,000 patients receive hospital and emergency room treatment for burns annually.
Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2217
On the other hand, the lack of donor for various transplantation procedures is expected to act as a challenge for clinicians around the globe. According to the U.S. government information on organ donation and transplantation, as of 2017, nearly 114,687 people in the U.S. were on waiting lists for transplants of kidneys, hearts, livers, and other organs. Tissue engineering can fulfill the inadequacy of organ transplantation and rising 3D printing prominence across medical applications for regeneration is projected to propel the demand for tissue engineering over the forecast timeframe. Furthermore, tissue engineering also holds a promising future for the restoration of 3D contour as well as the loss of function for the affected body parts.
Currently, available tissue engineering technique is facing several problems such as ineffective cell growth, insufficient, and unstable production of growth factors to stimulate cell communication and proper response and lack of suitable biomaterials and techniques for capturing appropriate physiological architectures. Moreover, the inability to control cellular functions and their various properties (biological, mechanical, electrochemical and others) and issues of biomolecular detection and biosensors are some of the other limitations associated with the tissue engineering market.
Request Customization Report@ https://www.coherentmarketinsights.com/insight/request-customization/2217
Furthermore, despite the growing interest in tissue engineering research, progress has been hampered by ethical and legislative debates. For instance, the ethical, political, and religious opposition for embryonic stem cell research, which primarily uses discarded non-transferred human embryos for their derivation, have biased research toward adult stem cells and severely restricted federal funding in the U.S.
Based on the region, the global tissue engineering market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is projected to foresee significant growth by 2026, and this can be attributed to rising geriatric population base rates and research studies in the field of tissue engineering. For instance, in August 2018, bioengineers at the Pennsylvania State University developed a composite ink to 3-D print porous, bone-like constructs. The materials showed biologically favorable interactions in the laboratory, followed by positive outcomes of bone regeneration in an animal model in vivo.
Europe's tissue engineering market is expected to grow at a significant rate, and this can be attributed to the presence of various public and private organizations highly engaged in the tissue engineering research field. For instance, in the UK, most tissue engineering research takes place in universities and much of the funding comes from organizations supporting the development of bioengineered organs for drug testing, such as Refinement and Reduction of Animals in Research (NC3Rs) National Centre for the Replacement and the EU's Innovative Medicines Initiative.
Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2217
Key players operating in the global tissue engineering market include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI Surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.